Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Aerobic exercise reduces asthma phenotype by inhibition of JAK2, SOCS3 and STAT6 in airway epithelium and in peribronchial leukocytes Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases Year: 2016
IL-37 requires IL18Rα and SIGIRR to diminish experimental allergic airway inflammation in mice Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015
LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Aerobic training reverses the inhibition in the expression of glucocorticoid receptors and decreases the Th2 allergic inflammation in asthma model Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013
Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016
Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014
LATE-BREAKING ABSTRACT: IL-5-induced airways eosinophilia as a negative regulator of TLR7 expression may impair the interferon response to rhinovirus in allergic airways Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014
LATE-BREAKING ABSTRACT: Morin attenuates ovalbumin-induced airway inflammation by modulating oxidative stress-responsive MAPK signaling Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases Source: International Congress 2015 – Translational studies in airway cell biology Year: 2015
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014
LATE-BREAKING ABSTRACT: TSLP as a potent activator of Th2 response in obstructive lung diseases Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016
Low power laser (LBP) therapy downregulates the allergic lung inflammation in experimental asthma model: Effect driven to signal transducer and activator of transduction 6 (STAT-6) Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013
Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013